PF-3845

Chemical compound
  • None
Legal statusLegal status
  • US: Investigational New Drug
Identifiers
  • N-3-pyridinyl-4-([3-([5-(trifluoromethyl)-2-pyridinyl]oxy)phenyl]methyl)-1-piperidinecarboxamide
CAS Number
  • 1196109-52-0
PubChem CID
  • 25154867
ChemSpider
  • 26232165
UNII
  • Q3PW846TYN
CompTox Dashboard (EPA)
  • DTXSID40648905 Edit this at Wikidata
Chemical and physical dataFormulaC24H23F3N4O2Molar mass456.469 g·mol−13D model (JSmol)
  • Interactive image
  • O=C(NC1=CN=CC=C1)N(CC2)CCC2CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3
InChI
  • InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32)
  • Key:NBOJHRYUGLRASX-UHFFFAOYSA-N

PF-3845 is a selective inhibitor of fatty acid amide hydrolase.[1] It results in increased levels of anandamide and results in cannabinoid receptor-based effects. It has anti-inflammatory action in mice colitis models. Antidiarrheal and antinociceptive effects were also seen in mouse models of pain.[2]

A 2017 study published in the Journal of Psychiatry and Neuroscience found that PF-3845 exerts rapid and long-lasting anti-anxiety effects in mice exposed acutely to stress or chronically to the stress hormone corticosterone.[3]

References

  1. ^ Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (April 2009). "Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain". Chemistry & Biology. 16 (4): 411–20. doi:10.1016/j.chembiol.2009.02.013. PMC 2692831. PMID 19389627.
  2. ^ Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. (April 2014). "Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides". Neurogastroenterology and Motility. 26 (4): 470–81. doi:10.1111/nmo.12272. PMID 24460851. S2CID 2473356.
  3. ^ Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. (June 2017). "Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents". Journal of Psychiatry & Neuroscience. 42 (4): 230–241. doi:10.1503/jpn.160116. PMC 5487270. PMID 28234213.
  • v
  • t
  • e
Receptor
(ligands)
CB1Tooltip Cannabinoid receptor type 1
Agonists
(abridged,
full list)
Inverse agonists
Antagonists
CB2Tooltip Cannabinoid receptor type 2
Agonists
Antagonists
NAGly
(GPR18)
Agonists
Antagonists
GPR55
Agonists
Antagonists
GPR119
Agonists
Transporter
(modulators)
eCBTsTooltip Endocannabinoid transporter
Enzyme
(modulators)
FAAHTooltip Fatty acid amide hydrolase
  • Activators: PDP-EA
MAGL
ABHD6
  • Inhibitors: JZP-169
  • JZP-430
  • KT182
  • KT185
  • KT195
  • KT203
  • LEI-106
  • ML294
  • ML295
  • ML296
  • UCM710
  • WWL-70
ABHD12
Others
  • Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
  • ARN-272 (FAAH-like anandamide transporter inhibitor)
See also
Receptor/signaling modulators
Cannabinoids (cannabinoids by structure)